PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 16531924-9 2006 RESULTS: 99mTc-EDDA/HYNIC-[Lys 3]-bombesin was obtained with radiochemical purities >93% and high specific activity ( approximately 0.1 GBq.nmol). GBQ 139-142 gastrin releasing peptide Homo sapiens 34-42 17138749-7 2006 The specific activity of (64)Cu-DOTA-VEGF(121) was 3.2 +/- 0.1 GBq/mg with a radiochemical purity of >98%. GBQ 63-66 vascular endothelial growth factor A Homo sapiens 37-41 18265976-3 2008 METHODS: Abs to EGFr or HER-2 were labeled with (111)In to a high specific activity of approximately 1.48 GBq/mg (40 mCi/mg). GBQ 106-109 epidermal growth factor receptor Mus musculus 16-20 17177894-4 2006 With N-succinimidyl 4-[18F] fluorobenzoate as labeling prosthetic group, [18F]FB-[R(8,15,21), L17]-VIP was obtained in >99% radiochemical purity within 100 min in decay-for-corrected radiochemical yield of 33.6 +/- 3% (n = 5) and a specific radioactivity 255 GBq/micromol at the end of synthesis. GBQ 262-265 skull development traits QTL 10 Mus musculus 94-102 11845839-1 2002 The U.S. NRC in 1997 removed its arbitrary 1.11 GBq (30 mCi) rule, which had been in existence for almost 50 y, and now many more patients receiving radionuclide therapy in nuclear medicine can be treated as outpatients. GBQ 48-51 nuclear receptor coactivator 6 Homo sapiens 9-12 15246372-3 2004 Using 3.7 GBq of [18F]F- as starting activity, [18F]FLT was obtained with a yield of 50.5 +/- 5.2% (n = 28, decay corrected) within 60.0 +/- 5.4 min including HPLC purification. GBQ 10-13 fms related receptor tyrosine kinase 1 Homo sapiens 52-55 14499336-5 2003 Optimal labeling yields were obtained when 60-90 microgram Hynic-Annexin V was labeled with up to 1.11 GBq (30 mCi) (99m)TcO(4)-using 10-20 microgram SnCl(2).2H(2)O as reducing agent and 1.5 mg tricine as the co-ligand. GBQ 103-106 annexin A5 Homo sapiens 65-74 14523936-1 2003 Following the first synthesis of tritiated alpha-melanocyte-stimulating hormone (alpha-MSH, alpha-melanotropin) in 1974 by Medzihradszky et al., several alpha-MSH analogs were designed containing between 2 and 12 tritium atoms, the latter of which displayed a specific radioactivity of 12.21 GBq/micromol (330 Ci/mmol). GBQ 292-295 pro-opiomelanocortin-alpha Mus musculus 153-162 14523936-2 2003 Similarly, radioiodinated alpha-MSH analogs of high purity, full biological activity and a specific radioactivity of approximately 140 GBq/micromol were obtained. GBQ 135-138 pro-opiomelanocortin-alpha Mus musculus 26-35 12121130-10 2002 On the nca level, the ligands allow labeling yields >95% with [(188)Re(H(2)O)(3)(CO)(3)](+) under mild reaction conditions (PBS buffer, 60 degrees C, 60 min) at ligand concentrations between 5 x 10(-4) M and 5 x 10(-5) M. Thus, specific activities of 22-220 GBq pe micromol of ligand could be achieved. GBQ 261-264 CEA cell adhesion molecule 6 Homo sapiens 7-10 16096583-8 2005 RESULTS: Re labelled anti-CD20 was obtained with high radiochemical purities (>97%) and high specific activity (0.5-0.7 GBq . GBQ 123-126 membrane-spanning 4-domains, subfamily A, member 1 Mus musculus 26-30 16155744-2 2005 METHODS: PET studies were conducted in 10 healthy male volunteers using a novel selective, high-affinity NK(1) receptor antagonist labeled with fluorine-18 to very high specific radioactivity (up to 2000 GBq/micromol) [F-18]SPA-RQ. GBQ 204-207 tachykinin receptor 1 Homo sapiens 105-119 34946596-8 2021 Radiolabeling experiments synthesized (165Er)PSMA-617 at DC molar activities of 37-130 GBq micromol-1. GBQ 87-90 folate hydrolase 1 Homo sapiens 45-49 10634383-13 2000 The serum Tg level obtained after withdrawal of T4 treatment permits the selection of patients with a Tg level exceeding 10 ng/mL, for scanning with 3.7 GBq (100 mCi). GBQ 153-156 thyroglobulin Homo sapiens 10-12 9394287-5 1997 The approximate dose rate at a radial distance of 1.5 mm from the center of the source was found to be 6.75 cGy/s per GBq (0.25 cGy/s per mCi), which allows the delivery of a therapeutic dose in a short time interval with a satisfactory homogeneity without stepping the source. GBQ 118-121 multiciliate differentiation and DNA synthesis associated cell cycle protein Mus musculus 138-141 34887335-8 2021 The mean whole-body dose of 177Lu-PSMA-617 was higher as compared to 177Lu-PSMA-I&T (0.04 Gy/GBq vs. 0.03 Gy/GBq, p<0.00001). GBQ 93-96 folate hydrolase 1 Homo sapiens 34-38 34887335-9 2021 Despite the longer half-life of 177Lu-PSMA-617, the renal dose of 177Lu-PSMA-617 was lower than for 177Lu-PSMA-I&T (0.77 Gy/GBq vs 0.92 Gy/GBq, P = 0.0015). GBQ 124-127 folate hydrolase 1 Homo sapiens 38-42 34887335-11 2021 Among all normal organs, lacrimal glands exhibited the highest mean absorbed dose of 5.1 Gy/GBq and 3.7 Gy/GBq for 177Lu-PSMA-617 and 177Lu-PSMA I&T, respectively. GBQ 92-95 folate hydrolase 1 Homo sapiens 121-125 34887335-11 2021 Among all normal organs, lacrimal glands exhibited the highest mean absorbed dose of 5.1 Gy/GBq and 3.7 Gy/GBq for 177Lu-PSMA-617 and 177Lu-PSMA I&T, respectively. GBQ 92-95 folate hydrolase 1 Homo sapiens 140-144 34887335-11 2021 Among all normal organs, lacrimal glands exhibited the highest mean absorbed dose of 5.1 Gy/GBq and 3.7 Gy/GBq for 177Lu-PSMA-617 and 177Lu-PSMA I&T, respectively. GBQ 107-110 folate hydrolase 1 Homo sapiens 121-125 34887335-11 2021 Among all normal organs, lacrimal glands exhibited the highest mean absorbed dose of 5.1 Gy/GBq and 3.7 Gy/GBq for 177Lu-PSMA-617 and 177Lu-PSMA I&T, respectively. GBQ 107-110 folate hydrolase 1 Homo sapiens 140-144 34469602-5 2021 Therapeutic dose of 177 Lu-PSMA-617 PRLT was 4.4-5.55 GBq per patient per cycle administered at intervals of 10-12 weeks in both groups. GBQ 54-57 folate hydrolase 1 Homo sapiens 27-31 34168013-8 2022 Significant uptake and long tumor retention of 177Lu-FAP-2286 resulted in high absorbed tumor doses, e.g., 3.0 +- 2.7 Gy/GBq (range 0.5 - 10.6) in bone metastases. GBQ 121-124 fibroblast activation protein alpha Homo sapiens 53-56 32379495-9 2021 Results: The average activity of 177Lu-PSMA-617 (mean +- SD) administered per patient per cycle was 4.94 +- 0.45 GBq. GBQ 113-116 folate hydrolase 1 Homo sapiens 39-43 2994048-2 1985 Murine TNF was radioiodinated to a specific activity of 1 mCi/nmol (1 Ci = 37 GBq) of monomer. GBQ 78-81 tumor necrosis factor Mus musculus 7-10 2911594-5 1989 The IFN-alpha A-P proteins can be phosphorylated by the catalytic subunit of cAMP-dependent protein kinase with [gamma-32P]ATP to high specific activity (2000-5000 Ci/mmol; 1 Ci = 37 GBq) with retention of biological activity. GBQ 183-186 interferon alpha 2 Homo sapiens 4-13 3438497-3 1987 were found in 99mTc generators with maximum level of 740 Bq/3.7 GBq (0.02 muCi/100 mCi) at one year after the reference date. GBQ 64-67 multiciliate differentiation and DNA synthesis associated cell cycle protein Mus musculus 83-86 7178542-1 1982 125I-labelled gastrin with high immunological activity and high specific radioactivity of 22.2 approximately 25.9 GBq (600 approximately mCi)/mg (0.5 iodine atom/1 gastrin molecule) was prepared by chloramine-T method using the amount of 100 molar ratio of chloramine-T to gastrin. GBQ 114-117 gastrin Homo sapiens 14-21 32379495-17 2021 The highest absorbed organ dose was observed in lacrimal glands and being a dose limiting organ, a cumulative activity up to 32.5 GBq (878 mCi) of 177Lu-PSMA-617 in 4-5 therapy cycles appears safe and feasible to achieve full therapeutic window. GBQ 130-133 folate hydrolase 1 Homo sapiens 153-157 30473431-4 2019 The 177Lu-PSMA-I&T was given 6-8 weekly with an activity of 7.4 GBq up to six cycles. GBQ 68-71 folate hydrolase 1 Homo sapiens 10-14 32062682-15 2020 Moreover, 7.5 GBq of [177Lu]Lu-PSMA-617 every 6 weeks causes slightly higher, though not statistically significant, response rates and seems therefore to be the preferable treatment regime. GBQ 14-17 folate hydrolase 1 Homo sapiens 31-35 31077356-7 2019 177 Lu-DOTAGA-PEG2 -RM26 demonstrated quantitative labeling yield at high molar activity (450 GBq/mumol), high in vivo stability (5 min pi >98% of radioligand remained when coinjected with phosphoramidon), high affinity to GRPR (KD = 0.4 +- 0.2 nM), and favorable biodistribution (1 hr pi tumor uptake was higher than in healthy tissues, including the kidneys). GBQ 94-97 insulin-like growth factor 2 Mus musculus 14-18 31731831-4 2019 The new radioligand [18F]BIT1 was obtained with a high radiochemical yield (54 +- 2%, n = 3), a high radiochemical purity (>=99%), and high molar activities (155-175 GBq/mumol, n = 3). GBQ 166-169 peptidyl-tRNA hydrolase 2 Mus musculus 25-29 30671739-8 2019 RESULTS: [68Ga]Ga-NOTA-anti-MMR-sdAb was obtained with 76 +- 2 % radiochemical yield, 99 +- 1 % radiochemical purity, and apparent molar activity of 57 +- 11 GBq/mumol. GBQ 158-161 ATPase, class II, type 9B Mus musculus 28-31 32358086-3 2020 Group B (n = 10) were treated with 2.12 +- 0.19 GBq/dose of 177Lu-EB-PSMA. GBQ 48-51 folate hydrolase 1 Homo sapiens 69-73 32358086-4 2020 Group C (n = 8) were treated with 3.52 +- 0.58 GBq/dose of 177Lu-EB-PSMA. GBQ 47-50 folate hydrolase 1 Homo sapiens 68-72 32358086-10 2020 Conclusion: This study demonstrates that 2.12 GBq/dose of 177Lu-EB-PSMA seems to be safe and adequate in tumor treatment. GBQ 46-49 folate hydrolase 1 Homo sapiens 67-71 30389816-7 2019 Results: The projected dosimetry for 90Y-PSMA-617 estimated a mean kidney dose of 3.47 +- 1.40 Gy/GBq, red marrow dose of 0.11 +- 0.04 Gy/GBq, and salivary gland dose of 5.57 +- 1.34 Gy/GBq; randomly chosen metastases were approximated with 22.8 +- 16.10 Gy/GBq. GBQ 98-101 folate hydrolase 1 Homo sapiens 41-45 30389816-7 2019 Results: The projected dosimetry for 90Y-PSMA-617 estimated a mean kidney dose of 3.47 +- 1.40 Gy/GBq, red marrow dose of 0.11 +- 0.04 Gy/GBq, and salivary gland dose of 5.57 +- 1.34 Gy/GBq; randomly chosen metastases were approximated with 22.8 +- 16.10 Gy/GBq. GBQ 138-141 folate hydrolase 1 Homo sapiens 41-45 30389816-7 2019 Results: The projected dosimetry for 90Y-PSMA-617 estimated a mean kidney dose of 3.47 +- 1.40 Gy/GBq, red marrow dose of 0.11 +- 0.04 Gy/GBq, and salivary gland dose of 5.57 +- 1.34 Gy/GBq; randomly chosen metastases were approximated with 22.8 +- 16.10 Gy/GBq. GBQ 138-141 folate hydrolase 1 Homo sapiens 41-45 30389816-7 2019 Results: The projected dosimetry for 90Y-PSMA-617 estimated a mean kidney dose of 3.47 +- 1.40 Gy/GBq, red marrow dose of 0.11 +- 0.04 Gy/GBq, and salivary gland dose of 5.57 +- 1.34 Gy/GBq; randomly chosen metastases were approximated with 22.8 +- 16.10 Gy/GBq. GBQ 138-141 folate hydrolase 1 Homo sapiens 41-45 31069008-9 2019 Twenty-two patients who received LuPRLT with a cumulative injected 177Lu activity >= 14.8 GBq had a better PSMA PET/CT progression-free survival than 23 patients who received LuPRLT with a lower cumulative injected 177Lu activity. GBQ 93-96 folate hydrolase 1 Homo sapiens 110-114 29466853-5 2018 Radiolabeled NK1R-NOTA was obtained with a radiochemical purity of >95% and specific activities of >7.0 GBq/mumol for 64Cu and >5.0 GBq/mumol for 67Ga. GBQ 110-113 tachykinin receptor 1 Homo sapiens 13-17 28798031-0 2018 Repeated 177Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. GBQ 92-95 folate hydrolase 1 Homo sapiens 23-27 29282518-10 2018 Accumulated activities of 30 to 50 GBq of 177Lu-PSMA ligands seem to be clinically safe with biochemical response and PERCIST/RECIST response in around 75% of patients along with xerostomia in 5-10% of patients as the only notable side effect. GBQ 35-38 folate hydrolase 1 Homo sapiens 48-52 27508105-9 2016 [(18)F]FBz-scFv-B43.13 was prepared in radiochemical yields of 3.7 +- 1.8% (n = 5) at an effective specific activity of 3.88 +- 0.76 GBq/micromol (n = 5). GBQ 133-136 immunglobulin heavy chain variable region Homo sapiens 11-15 27264278-4 2016 Extensive radiochemical studies were performed to optimize the required [PSMA-617] / [Lu] ratio and other parameters to formulate 7.4 GBq dose of (177) Lu-PSMA-617. GBQ 134-137 folate hydrolase 1 Homo sapiens 155-159 27264278-5 2016 Based on these, 7.4 GBq therapeutic dose of (177) Lu-PSMA-617 was formulated by incubating 160 microg of PSMA-617 with indigenously produced (177) LuCl3 (555 GBq/microg specific activity of (177) Lu) at 90 C for 30 min. GBQ 20-23 folate hydrolase 1 Homo sapiens 53-57 27264278-5 2016 Based on these, 7.4 GBq therapeutic dose of (177) Lu-PSMA-617 was formulated by incubating 160 microg of PSMA-617 with indigenously produced (177) LuCl3 (555 GBq/microg specific activity of (177) Lu) at 90 C for 30 min. GBQ 158-161 folate hydrolase 1 Homo sapiens 53-57 27264278-5 2016 Based on these, 7.4 GBq therapeutic dose of (177) Lu-PSMA-617 was formulated by incubating 160 microg of PSMA-617 with indigenously produced (177) LuCl3 (555 GBq/microg specific activity of (177) Lu) at 90 C for 30 min. GBQ 20-23 folate hydrolase 1 Homo sapiens 105-109 22973082-1 2012 This study aims to generate the normalized mean organ dose factors (mGy min(-1) GBq(-1)) to healthy organs during brachytherapy treatment of esophagus, breast, and neck cancers specific to the patient population in India. GBQ 80-83 CD59 molecule (CD59 blood group) Homo sapiens 72-78 26357962-6 2015 A bi-exponential regression model was developed between the MTA normalized to the patient"s BSA and the percent retention value at the 48-hour time point (R): MTA (GBq)/BSA (m(2)) = (13.91 e(-0.0387R) + 42.33 e(-0.8522R)). GBQ 164-167 methylthioadenosine phosphorylase Homo sapiens 60-63 26357962-6 2015 A bi-exponential regression model was developed between the MTA normalized to the patient"s BSA and the percent retention value at the 48-hour time point (R): MTA (GBq)/BSA (m(2)) = (13.91 e(-0.0387R) + 42.33 e(-0.8522R)). GBQ 164-167 methylthioadenosine phosphorylase Homo sapiens 159-162 24459669-4 2013 In this study, F-18 labeled [R(8,15,21), L(17)]-VIP was produced with the radiochemical yield being as high as 33.6% +- 3% (decay-for-corrected, n = 5) achieved within 100 min, a specific activity of 255 GBq/ mumol, and a radiochemical purity as high as 99% as characterized by radioactive HPLC, TLC, and SDS-Page radioautography. GBQ 204-207 vasoactive intestinal polypeptide Mus musculus 48-51 23096079-7 2013 RESULTS: The decay-corrected radiochemical yield of (68)Ga-NOTA-VEGF(121) was 40 +- 4.5 % and specific activity was 243.1 +- 104.6 GBq/mumol (8.6 +- 3.7 GBq/mg). GBQ 131-134 vascular endothelial growth factor A Homo sapiens 64-68 23096079-7 2013 RESULTS: The decay-corrected radiochemical yield of (68)Ga-NOTA-VEGF(121) was 40 +- 4.5 % and specific activity was 243.1 +- 104.6 GBq/mumol (8.6 +- 3.7 GBq/mg). GBQ 153-156 vascular endothelial growth factor A Homo sapiens 64-68 30042959-5 2016 Under non-optimized conditions, [18F]AlF-NOTA-pentixather was obtained in radiochemical yields of 45.5% +- 13.3% and specific activities of up to 24.8 GBq/mumol. GBQ 151-154 afamin Homo sapiens 37-40 27150032-3 2016 EXPERIMENTAL: Patient dose of 7.4 GBq (200 mCi) of (177)Lu-labeled PSMA-617 was prepared by incubating 100 mug of PSMA-617 with (177)LuCl3 at 95 C for 15 minutes. GBQ 34-37 folate hydrolase 1 Homo sapiens 67-71 26505525-5 2016 We have identified and radiolabeled a reversible FAAH inhibitor, 7-(2-[(11)C]methoxyphenyl)-1-(5-(pyridin-2-yl)oxazol-2-yl)heptan-1-one ([(11)C]MPPO) in 13% radiochemical yield (nondecay corrected) with >99% radiochemical purity and 2 Ci/mumol (74 GBq/mumol) specific activity. GBQ 251-254 fatty acid amide hydrolase Homo sapiens 49-53 25257474-7 2014 (18) F-FAC was obtained in radiochemical yields of 4.3-5.5% (n = 8, decay-corrected from end of bombardment), with purities >=98% and specific activities >=63 GBq/micromol. GBQ 165-168 FA complementation group C Homo sapiens 7-10 22608919-3 2012 Radiomethylation of 7 with [(11)C]CH(3)I afforded [(11)C]rac-1 in an average radiochemical yield of 30 +- 5% (n=5) with high radiochemical purity and an average specific radioactivity of 444 +- 74 GBq/mumol (n=5). GBQ 197-200 Rac family small GTPase 1 Mus musculus 57-62 20870158-2 2010 Recently, we succeeded in synthesizing [(11)C]raclopride, a dopamine D(2) receptor ligand, with ultra-high specific radioactivity, i.e., several thousand GBq/mumol. GBQ 154-157 dopamine receptor D2 Homo sapiens 60-82 20705143-1 2011 The aim of this study was to visualize early infarction in the rat brain after ischemia using a translocator protein (TSPO) (18 kDa) PET ligand [(11)C]DAC with ultra-high specific activity (SA) of 3670-4450 GBq/mumol. GBQ 207-210 translocator protein Rattus norvegicus 96-116 20705143-1 2011 The aim of this study was to visualize early infarction in the rat brain after ischemia using a translocator protein (TSPO) (18 kDa) PET ligand [(11)C]DAC with ultra-high specific activity (SA) of 3670-4450 GBq/mumol. GBQ 207-210 translocator protein Rattus norvegicus 118-122 20705143-3 2011 Early infarction with a small increase of TSPO expression in the brain was visualized using PET with high SA [(11)C]DAC (average 4060 GBq/mumol), but was not distinguished clearly with usually reported SA [(11)C]DAC (37 GBq/mumol). GBQ 134-137 translocator protein Rattus norvegicus 42-46 20705143-3 2011 Early infarction with a small increase of TSPO expression in the brain was visualized using PET with high SA [(11)C]DAC (average 4060 GBq/mumol), but was not distinguished clearly with usually reported SA [(11)C]DAC (37 GBq/mumol). GBQ 220-223 translocator protein Rattus norvegicus 42-46 18784964-5 2009 RESULTS: The specific activity of (64)Cu-DOTA-VEGF(121) was 3.2 GBq/mg. GBQ 64-67 vascular endothelial growth factor A Homo sapiens 46-50 19856257-4 2010 Knowledge of comparative remnant radioiodine kinetics, particularly the remnant radiation dose in Gy/GBq of administered (131)I activity (RDpA), could assist in choosing rhTSH-aided ablative activities. GBQ 101-104 RDPA Homo sapiens 138-142